Concanamycin A is the major analogue of the concanamycin complex produced by Streptomyces sp.. It has been shown to act as a potent and specific vacuolar-ATPase inhibitor. Concanamycin A inhibits the acidification of organelles and blocks cell surface expression of viral envelope glycoproteins without affecting their synthesis. It also interferes with intracellular protein trafficking and inhibits perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Concanamycins are structurally related to the bafilomycins.
Concanamycin A is soluble in ethanol, methanol, DMF and DMSO.
Concanamycin A is soluble in ethanol, methanol, DMF and DMSO.
| Mechanism of Action | Concanamycin A inhibits the acidification of organelles and blocks cell surface expression of viral envelope glycoproteins without affecting their synthesis. It also interferes with intracellular protein trafficking and inhibits perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. |
| References | The V-ATPase inhibitors concanamycin A and bafilomycin A lead to Golgi swelling in tobacco BY-2 cells. Robinson D.G. et al. , Protoplasma 2004, 224, 255. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Kataoka T. et al. , J. Immunol. 1996, 156, 3678. Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death. Nishihara T. et al. , Biochem. Biophys. Res. Commun. 1995, 212, 255. Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus. Muroi M. et al. , Cell Struct. Funct. 1993, 18, 139. |
